Quality of life and decision regret in patients with late-hypothyroidism after radioiodine treatment for Graves' disease

被引:1
作者
Li, Yue [1 ]
Yang, Tianyu [1 ]
Ju, Linjun [1 ]
Feng, Yuyue [1 ]
Chen, Zheng [1 ]
Xiang, Xing [1 ]
Zhu, Tao [1 ]
Pang, Hua [1 ]
Wang, Zhengjie [1 ]
机构
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Nucl Med, Chongqing 400016, Peoples R China
关键词
decision regret; Graves' disease; QoL; radioiodine; ThyPRO-39; CLINICAL MANAGEMENT; HYPERTHYROIDISM; OPHTHALMOPATHY; GUIDELINES; THERAPY;
D O I
10.1111/cen.14986
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Patients with Graves' disease often engage in shared decision-making to select an individualised treatment regimen from multiple options. Radioactive iodine (RAI) is one of the treatment choices for their condition, aims to improve quality of life and well-being. Likewise, dissatisfaction with treatment outcomes can result in decision regret. We employed validated questionnaires to assess the prospective quality of life, decision regret and relative factors involved in decision-making of patients with late hypothyroidism after RAI therapy.Methods: A questionnaire survey was conducted among patients in hypothyroidism status for more than 1 year after RAI therapy. Disease-specific and generic QoL were assessed using the short form of thyroid-related patient-reported outcome (ThyPRO-39) questionnaire. Patient satisfaction regarding their decision to undergo RAI was assessed using the Decision Regret Scale (DRS) and patients were asked about the importance of relative factors in decision-making.Results: Of 254 patients who responded to the survey, the mean age of patients was 45.3 years (range: 18-78 years) and the median time from RAI therapy to survey was 4 years (range: 1-30 years). Patients' median and mean DRS score were 34.4 and 38.8 (range: 0-100), respectively. A total of 100 (39.4%) patients express absent-to-mild regret (score: 0-25), 154 (60.6%) patients express moderate-to-severe regret (score: >25). The mean score of the absent-to-mild regret group were significantly higher than those of the moderate-to-severe regret group on most ThyPRO-39 scales. A statistically significant positive correlation was observed between DRS score and most ThyPRO-39 scale score. There was a significant positive association between higher DRS score and longer time intervals after RAI treatment, a brief duration of hyperthyroidism, and the significance of long-time outpatient follow-up. More decision regret was negatively associated Iodine-free diet, ineffectiveness of ATD, fear of surgery.Conclusion: Impairment of quality of life was positively correlated with decision regret in patients with late-hypothyroidism after radioiodine therapy. Patients with insufficient information support before decision-making are more likely to have higher decision regret after treatment. Our findings suggest that health providers should fully communicate with patients and provide information support in multiple dimensions during the shared-decision-making process.
引用
收藏
页码:87 / 95
页数:9
相关论文
共 33 条
[1]   Radioiodine therapy (RAI) for Graves' disease (GD) and the effect on ophthalmopathy: a systematic review [J].
Acharya, Shamasunder H. ;
Avenell, Alison ;
Philip, Sam ;
Burr, Jennifer ;
Bevan, John S. ;
Abraham, Prakash .
CLINICAL ENDOCRINOLOGY, 2008, 69 (06) :943-950
[2]   An examination of machine learning to map non-preference based patient reported outcome measures to health state utility values [J].
Aghdaee, Mona ;
Parkinson, Bonny ;
Sinha, Kompal ;
Gu, Yuanyuan ;
Sharma, Rajan ;
Olin, Emma ;
Cutler, Henry .
HEALTH ECONOMICS, 2022, 31 (08) :1525-1557
[3]   The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy [J].
Bartalena, L. ;
Kahaly, G. J. ;
Baldeschi, L. ;
Dayan, C. M. ;
Eckstein, A. ;
Marcocci, C. ;
Marino, M. ;
Vaidya, B. ;
Wiersinga, W. M. .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2021, 185 (04) :G43-G67
[4]   Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease [J].
Brito, Juan P. ;
Castaneda-Guarderas, Ana ;
Gionfriddo, Michael R. ;
Ospina, Naykky Singh ;
Maraka, Spyridoula ;
Dean, Diana S. ;
Castro, Regina M. ;
Fatourechi, Vahab ;
Gharib, Hossein ;
Stan, Marius N. ;
Branda, Megan E. ;
Bahn, Rebecca S. ;
Montori, Victor M. .
THYROID, 2015, 25 (11) :1191-1198
[5]  
Cai Z., 2022, INT J ENDOCRINOL, V2022, P1
[6]   Validity and Reliability of the Decision Regret Scale in Cancer Patients Receiving Adjuvant Chemotherapy [J].
Calderon, Caterina ;
Joan Ferrando, Pere ;
Lorenzo-Seva, Urbano ;
Higuera, Oliver ;
Ramon y Cajal, Teresa ;
Rogado, Jacobo ;
Mut-Lloret, Margarida ;
Rodriguez-Capote, Alejandra ;
Jara, Carlos ;
Jimenez-Fonseca, Paula .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2019, 57 (04) :828-834
[7]   Treatment choice, satisfaction and quality of life in patients with Graves' disease [J].
Conaglen, Helen M. ;
Tamatea, Jade A. U. ;
Conaglen, John, V ;
Elston, Marianne S. .
CLINICAL ENDOCRINOLOGY, 2018, 88 (06) :977-984
[8]   Regret in cancer-related decisions [J].
Connolly, T ;
Reb, J .
HEALTH PSYCHOLOGY, 2005, 24 (04) :S29-S34
[9]   Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study [J].
Cramon, Per ;
Winther, Kristian Hillert ;
Watt, Torquil ;
Bonnema, Steen Joop ;
Bjorner, Jakob Bue ;
Ekholm, Ola ;
Groenvold, Mogens ;
Hegedus, Laszlo ;
Feldt-Rasmussen, Ulla ;
Rasmussen, Ase Krogh .
THYROID, 2016, 26 (08) :1010-1018
[10]   Impaired decision making under risky conditions in the acute phase of Graves' thyroitoxicosis [J].
Dai, Fang ;
Yuan, Lili ;
Fang, Juan ;
Zhang, Qiu ;
Wang, Kai .
NEUROSCIENCE LETTERS, 2017, 661 :1-4